We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Igm Biosciences Inc
5 own
6 watching
Current Price
$23.16
$0.43
(1.89%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
991.3M
52-Week High
35.98
52-Week Low
12.67
Average Volume
0.11M
Dividend Yield
--
P/E Ratio
--
Market Capitalization991.3M52-Week High35.9852-Week Low12.67Average Volume0.11MDividend Yield--P/E Ratio--What does the Igm Biosciences Inc do?
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Read More
How much money does Igm Biosciences Inc make?
News & Events about Igm Biosciences Inc.
PR Newswire
17days ago
Medivir to present at the Redeye Fight Cancer Day Medivir to present at the Redeye Fight Cancer Day PR Newswire STOCKHOLM, Jan. 16, 2023 STOCKHOLM, Jan. 16, 2023 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in...
Globe Newswire
24days ago
Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients Encouraging safety profile in combination with FOLFIRI chemotherapy Randomized combination trial in second-line colorectal cancer patients to initiate in Q1 2023 ...
Tickeron - Technical Analysis
1month ago
For the last three days, A.I.dvisor has detected that IGMS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for IGMS, and traders may view it as a Sell signal for the next month. Traders may consider ...
Ticker Report
1month ago
IGM Biosciences, Inc. (NASDAQ:IGMS Get Rating) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,230,000 shares, a decline of 9.3% from the November 15th total of 3,560,000 shares. Currently, 18.7...
Zolmax
1month ago
IGM Biosciences, Inc. (NASDAQ:IGMS Get Rating) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,230,000 shares, a decline of 9.3% from the November 15th total of 3,560,000 shares. Currently, 18.7% of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Igm Biosciences Inc share price today?
Can Indians buy Igm Biosciences Inc shares?
How can I buy Igm Biosciences Inc shares from India?
Can Fractional shares of Igm Biosciences Inc be purchased?
What are the documents required to start investing in Igm Biosciences Inc stocks?
What is today’s traded volume of Igm Biosciences Inc?
What is today’s market capitalisation of Igm Biosciences Inc?
What is the 52-Week High and Low Range of Igm Biosciences Inc?
What percentage is Igm Biosciences Inc down from its 52-Week High?
What percentage is Igm Biosciences Inc up from its 52-Week Low?
Current Price
$23.16
$0.43
(1.89%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.